Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers
Pharmacy Times
JULY 16, 2025
Tarlatamab established a new standard for relapsed SCLC, with improved survival and easier administration, enhancing treatment accessibility. 2 Vepdegestrant is an oral PROTAC that targets ER and is the first agent of its type to be evaluated in a phase 3 trial.
Let's personalize your content